-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

Benzinga·01/09/2026 14:12:50
Listen to the news
Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.